185 related articles for article (PubMed ID: 30566780)
1. 5-Aminosalicylic acid.
Iida T; Onodera K; Nakase H
Nihon Rinsho; 2017 Mar; 75(3):392-397. PubMed ID: 30566780
[TBL] [Abstract][Full Text] [Related]
2. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease.
Brzezinski A; Rankin GB; Seidner DL; Lashner BA
Cleve Clin J Med; 1995; 62(5):317-23. PubMed ID: 7586488
[TBL] [Abstract][Full Text] [Related]
3. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?
De Broe ME; Stolear JC; Nouwen EJ; Elseviers MM
Nephrol Dial Transplant; 1997 Sep; 12(9):1839-41. PubMed ID: 9306332
[No Abstract] [Full Text] [Related]
4. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
Ioffe AIu
Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
[TBL] [Abstract][Full Text] [Related]
5. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
[TBL] [Abstract][Full Text] [Related]
6. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
7. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
9. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
10. Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents.
Present DH
Gastroenterology; 2000 Jul; 119(1):276. PubMed ID: 10928833
[No Abstract] [Full Text] [Related]
11. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
12. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
Kao J; Kwok K; Das KM
J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466
[TBL] [Abstract][Full Text] [Related]
13. [Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?].
Allgayer H; Klotz U; Böhne P; Schmidt M; Kruis W
Z Gastroenterol; 1994 Nov; 32(11):647-50. PubMed ID: 7886975
[TBL] [Abstract][Full Text] [Related]
14. The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease.
Kadiyala I; Jacobs D
Recent Pat Drug Deliv Formul; 2014 Apr; 8(1):3-11. PubMed ID: 24111938
[TBL] [Abstract][Full Text] [Related]
15. 5-Aminosalicylic acid, a specific drug for ulcerative colitis.
Hauso Ø; Martinsen TC; Waldum H
Scand J Gastroenterol; 2015 Aug; 50(8):933-41. PubMed ID: 25733192
[TBL] [Abstract][Full Text] [Related]
16. Letter: switches of 5-aminosalicylates in ulcerative colitis, risk of relapse and ascertainment bias.
Curtis H; Jones S; Treasure P
Aliment Pharmacol Ther; 2014 Feb; 39(3):344-5. PubMed ID: 24397326
[No Abstract] [Full Text] [Related]
17. Drugs for inflammatory bowel disease.
Treat Guidel Med Lett; 2012 Mar; 10(115):19-28. PubMed ID: 22361569
[No Abstract] [Full Text] [Related]
18. Commentary: 5-ASA switches in IBD, adherence and flares.
Selinger CP
Aliment Pharmacol Ther; 2013 Nov; 38(9):1138. PubMed ID: 24099475
[No Abstract] [Full Text] [Related]
19. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
Bautzová T; Rabišková M; Lamprecht A
Drug Dev Ind Pharm; 2011 Sep; 37(9):1100-9. PubMed ID: 21417610
[TBL] [Abstract][Full Text] [Related]
20. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
Abinusawa A; Tenjarla S
Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
